VivoSeq
Infectious Disease

Bronchitis

32

Pipeline Programs↗

1

Active Trials↗

20

Companies Involved↗

Bronchitis is a moderately active landscape with 32 programs across 20 companies. The most active players are Teva, Roche, Prism Pharmaceuticals. 12 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

6/100

Mech. Concentration

18/100

Completion Rate

83/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 2Roche logo

Roche

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

5 programs

Phase 3J

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

33 of 36 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody26%Protein / enzyme13%

Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 97% of 37 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed10 · 45%
Unknown status9 · 41%
Terminated1 · 5%
Withdrawn1 · 5%
Recruiting1 · 5%

Clinical Trials

Trial Activity

22 trials

Multicenter, Double Blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients
Recruiting·MMateria Medica Holding·Phase 3·NCT07650227·308 enrolled
Tracheobronchitis Prevention Trial
Completed·UUniversity of Thessaly·N/A·NCT01025921·84 enrolled
Intravenous Magnesium in Wheezy Bronchitis
Completed·UUniversity of Oulu·N/A·NCT01383655·61 enrolled
Impact of Antibiotic Treatment on Outcome in Patients With Ventilator-Associated Tracheobronchitis
Completed·UUniversity Hospital, Lille·N/A·NCT00122057·58 enrolled
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT02173691·584 enrolled
Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
Completed·MMcMaster University·Phase 2/3·NCT02049294·11 enrolled
Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT02172326·29 enrolled
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT02233920·716 enrolled
Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients
Completed·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 4·NCT02002715·106 enrolled
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Completed·UUniversity of Michigan·Phase 2·NCT02315898·40 enrolled
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00269932·485 enrolled
Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
Terminated·UUniversity Hospital, Lille·Phase 4·NCT03012360·103 enrolled
Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis
Withdrawn·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT00726479
The Efficacy and Safety of Sirolimus for Plastic Bronchitis
Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT03942926·10 enrolled
The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma
Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 4·NCT02002754·45 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)